The role of peptide and DNA vaccines in myeloid leukemia immunotherapy

Cancer Cell International

Volumn 13, Issue 1, 2013, Pages

  Lin, Chen ^a   Li, Yangqiu ^a,b  

^a MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

^b JINAN UNIVERSITY   (China)

Author keywords

DNA vaccine; Immunotherapy; Leukemia associated antigen; Myeloid leukemia; Peptide vaccine

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN 70; IMATINIB; INTERLEUKIN 2; INTERLEUKIN 7; LEVAMISOLE; PEPTIDE; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; HUMAN; IMMUNOGENICITY; LEUKEMIA CELL; MINIMAL RESIDUAL DISEASE; MYELOID LEUKEMIA; PROMYELOCYTIC LEUKEMIA; REVIEW;

EID: 84873495994     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-13-13     Document Type: Review

References (66)

1. Yong AS, Keyvanfar K, Eniafe R, Savani BN, Rezvani K, Sloand EM, Goldman JM, Barrett AJ. Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy. Leukemia 2008, 22(9):1721-1727. 10.1038/leu.2008.161, 2574650, 18548092.
2. Ali N, Adil SN, Shaikh MU, Moosajee M, Masood N. Outcome of match related allogeneic stem cell transplantation procedures performed from 2004 till 2011. Exp Hematol Oncol 2012, 1(1):13. 10.1186/2162-3619-1-13, 3514083, 23210643.
3. Lu K, Wang X. Therapeutic advancement of chronic lymphocytic leukemia. J Hematol Oncol 2012, 5:55. 10.1186/1756-8722-5-55, 3465197, 22980425.
4. Collins RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, Goodman SA, Wolff SN, Hu W, Verfaillie C, List A, Dalton W, Ognoskie N, Chetrit A, Antin JH, Nemunaitis J. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997, 15(2):433-434.
5. Goldman JM, Druker BJ. Chronic myeloid leukemia: current treatment options. Blood 2001, 98(7):2039-2042. 10.1182/blood.V98.7.2039, 11567987.
6. Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, Storb R. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979, 300(19):1068-1073. 10.1056/NEJM197905103001902, 34792.
7. Greiner J, Dohner H, Schmitt M. Cancer vaccines for patients with acute myeloid leukemia - definition of leukemia-associated antigens and current clinical protocols targeting these antigens. Haematologica 2006, 91(12):1653-1661.
8. Harty JT, Badovinac VP. Shaping and reshaping CD8 + T-cell memory. Nat Rev Immunol 2008, 8(2):107-119. 10.1038/nri2251, 18219309.
9. Quintarelli C, Dotti G, De Angelis B, Hoyos V, Mims M, Luciano L, Heslop HE, Rooney CM, Pane F, Savoldo B. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood 2008, 112(5):1876-1885. 10.1182/blood-2008-04-150045, 3401035, 18591381.
10. Rezvani K, Yong AS, Mielke S, Jafarpour B, Savani BN, Le RQ, Eniafe R, Musse L, Boss C, Kurlander R, Barrett AJ. Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies. Haematologica 2011, 96(3):432-440. 10.3324/haematol.2010.031674, 3046275, 21134985.
11. Li Y, Lin C, Schmidt CA. New insights into antigen specific immunotherapy for chronic myeloid leukemia. Cancer Cell Int 2012, 12:52. 10.1186/1475-2867-12-52, 3538626, 23241263.
12. Stevenson FK, Ottensmeier CH, Rice J. DNA vaccines against cancer come of age. Curr Opin Immunol 2010, 22(2):264-270. 10.1016/j.coi.2010.01.019, 20172703.
13. Low L, Mander A, McCann K, Dearnaley D, Tjelle T, Mathiesen I, Stevenson F, Ottensmeier CH. DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum Gene Ther 2009, 20(11):1269-1278. 10.1089/hum.2009.067, 19619001.
14. Stevenson FK, Ottensmeier CH, Johnson P, Zhu D, Buchan SL, McCann KJ, Roddick JS, King AT, McNicholl F, Savelyeva N, Rice J. DNA vaccines to attack cancer. Proc Natl Acad Sci U S A 2004, 101(Suppl 2):14646-14652. 521995, 15292504.
15. Rinaldi M, Ria F, Parrella P, Signori E, Serra A, Ciafrè SA, Vespignani I, Lazzari M, Farace MG, Saglio G, Fazio VM. Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells. Cancer Res 2001, 161(4):1555-1562.
16. Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, van Beckhoven A, Liles TM, Engleman EG, Levy R. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002, 99(5):1517-1526. 10.1182/blood.V99.5.1517, 11861263.
17. Maecker HT, Umetsu DT, DeKruyff RH, Levy S. Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC. Immunology 1998, 161(12):6532-6536.
18. Chan K, Lee DJ, Schubert A, Tang CM, Crain B, Schoenberger SP, Corr M. The roles of MHC class II, CD40, and B7 costimulation in CTL induction by plasmid DNA. J Immunol 2001, 166(5):3061-3066.
19. Pfaar O, Cazan D, Klimek L, Larenas-Linnemann D, Calderon MA. Adjuvants for immunotherapy. Curr Opin Allergy Clin Immunol 2012, 12(6):648-657. 10.1097/ACI.0b013e32835a11d6, 23090384.
20. Wang Z, Choi MK, Ban T, Yanai H, Negishi H, Lu Y, Tamura T, Takaoka A, Nishikura K, Taniguchi T. Regulation of innate immune responses by DAI (DLM-1/ZBP1) and other DNA-sensing molecules. Proc Natl Acad Sci USA 2008, 105(14):5477-5482. 10.1073/pnas.0801295105, 2291118, 18375758.
21. Burckstummer T, Baumann C, Bluml S, Dixit E, Durnberger G, Jahn H, Planyavsky M, Bilban M, Colinge J, Bennett KL, Superti-Furga G. An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat Immunol 2009, 10(3):266-272. 10.1038/ni.1702, 19158679.
22. Mincheff M, Tchakarov S, Zoubak S, Loukinov D, Botev C, Altankova I, Georgiev G, Petrov S, Meryman HT. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial. Eur Urol 2000, 38(2):208-217. 10.1159/000020281, 10895014.
23. Rosenberg SA, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, White DE. Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum Gene Ther 2003, 14(8):709-714. 10.1089/104303403765255110, 2078240, 12804135.
24. Tagawa ST, Lee P, Snively J, Boswell W, Ounpraseuth S, Lee S, Hickingbottom B, Smith J, Johnson D, Weber JS. Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma. Cancer 2003, 98(1):144-154. 10.1002/cncr.11462, 12833467.
25. Timmerman JM, Singh G, Hermanson G, Hobart P, Czerwinski DK, Taidi B, Rajapaksa R, Caspar CB, Van Beckhoven A, Levy R. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res 2002, 62(20):5845-5852.
26. Zha X, Yan X, Shen Q, Zhang Y, Wu X, Chen S, Li B, Yang L, Geng S, Weng J, Du X, Li Y. Alternative expression of TCRζ related genes in patients with chronic myeloid leukemia. J Hematol Oncol 2012, 5:74. 10.1186/1756-8722-5-74, 3544630, 23228155.
27. Rojas JM, Knight K, Watmough S, Bell J, Wang L, Callaghan T, Clark RE. BCR-ABL peptide vaccination in healthy subjects: immunological responses are equivalent to those in chronic myeloid leukaemia patients. Leuk Res 2011, 35(3):369-372. 10.1016/j.leukres.2010.05.028, 20573399.
28. Cathcart K, Pinilla-Ibarz J, Korontsvit T, Schwartz J, Zakhaleva V, Papadopoulos EB, Scheinberg DA. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 2004, 103(3):1037-1042.
29. Bocchia M, Gentili S, Abruzzese E, Fanelli A, Iuliano F, Tabilio A, Amabile M, Forconi F, Gozzetti A, Raspadori D, Amadori S, Lauria F. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 2005, 365(9460):657-662.
30. Kessler JH, Bres-Vloemans SA, van Veelen PA, de Ru A, Huijbers IJ, Camps M, Mulder A, Offringa R, Drijfhout JW, Leeksma OC, Ossendorp F, Melief CJ. BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes. Leukemia 2006, 20(10):1738-1750. 10.1038/sj.leu.2404354, 16932347.
31. Maslak PG, Dao T, Gomez M, Chanel S, Packin J, Korontsvit T, Zakhaleva V, Pinilla-Ibarz J, Berman E, Scheinberg DA. A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease. Leukemia 2008, 22(8):1613-1616. 10.1038/leu.2008.7, 18256684.
32. Jain N, Reuben JM, Kantarjian H, Li C, Gao H, Lee BN, Cohen EN, Ebarb T, Scheinberg DA, Cortes J. Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. Cancer 2009, 115(17):3924-3934. 10.1002/cncr.24468, 19536894.
33. Breccia M, Bocchia M, Cannella L, Defina M, Ippoliti M, Loglisci G, Santopietro M, Lauria F, Alimena G. Reduction of imatinib dose and persistence of complete molecular response after p210 multipeptide vaccine in chronic myeloid leukaemia treated with dose escalation for acquired resistance. Br J Haematol 2010, 150(2):240-242.
34. Lucansky V, Sobotkova E, Tachezy R, Duskova M, Vonka V. DNA vaccination against bcr-abl-positive cells in mice. Int J Oncol 2009, 35(4):941-951.
35. Osman Y, Takahashi M, Zheng Z, Toba K, Liu A, Furukawa T, Narita M, Aizawa Y, Koike T, Shibata A. Dendritic cells stimulate the expansion of PML-RAR alpha specific cytotoxic T-lymphocytes: its applicability for antileukemia immunotherapy. J Exp Clin Cancer Res 1999, 18(4):485-492.
36. Padua RA, Chomienne C. Use of animal models for the treatment of leukemias: Efficacy of DNA vaccination combined with ATRA. Discov Med 2004, 4(20):41-44.
37. Padua RA, Larghero J, Robin M, le Pogam C, Schlageter MH, Muszlak S, Fric J, West R, Rousselot P, Phan TH, Mudde L, Teisserenc H, Carpentier AF, Kogan S, Degos L, Pla M, Bishop JM, Stevenson F, Charron D, Chomienne C. PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia. Nat Med 2003, 9(11):1413-1417. 10.1038/nm949, 14566333.
38. Pollock JL, Lane AA, Schrimpf K, Ley TJ. Murine acute promyelocytic leukemia cells can be recognized and cleared in vivo by adaptive immune mechanisms. Haematologica 2005, 90(8):1042-1049.
39. Furugaki K, Pokorna K, Le Pogam C, Aoki M, Reboul M, Bajzik V, Krief P, Janin A, Noguera ME, West R, Charron D, Chomienne C, Pla M, Moins-Teisserenc H, Padua RA. DNA vaccination with all-trans retinoic acid treatment induces long-term survival and elicits specific immune responses requiring CD4+ and CD8+ T-cell activation in an acute promyelocytic leukemia mouse model. Blood 2010, 115(3):653-656. 10.1182/blood-2007-08-109009, 19965687.
40. Oka Y, Tsuboi A, Kawakami M, Elisseeva OA, Nakajima H, Udaka K, Kawase I, Oji Y, Sugiyama H. Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers. Curr Med Chem. 2006, 13(20):2345-2352. 10.2174/092986706777935104, 16918359.
41. Ochsenreither S, Fusi A, Busse A, Bauer S, Scheibenbogen C, Stather D, Thiel E, Keilholz U, Letsch A. " Wilms Tumor Protein 1" (WT1) peptide vaccination-induced complete remission in a patient with acute myeloid leukemia is accompanied by the emergence of a predominant T-cell clone both in blood and bone marrow. J Immunother 2011, 34(1):85-91. 10.1097/CJI.0b013e3181f3cc5c, 21150716.
42. Ochsenreither S, Fusi A, Geikowski A, Stather D, Busse A, Stroux A, Letsch A, Keilholz U. Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3β sequence associated with remission in one patient is detectable in other vaccinated patients. Cancer Immunol Immunother 2012, 61(3):313-322. 10.1007/s00262-011-1099-y, 21898091.
43. Oji Y, Oka Y, Nishida S, Tsuboi A, Kawakami M, Shirakata T, Takahashi K, Murao A, Nakajima H, Narita M, Takahashi M, Morita S, Sakamoto J, Tanaka T, Kawase I, Hosen N, Sugiyama H. WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient. Eur J Haematol 2010, 85(4):358-360. 10.1111/j.1600-0609.2010.01497.x, 20633041.
44. Saitoh A, Narita M, Watanabe N, Tochiki N, Yamahira A, Nakamura T, Kaji M, Masuko M, Furukawa T, Toba K, Fuse I, Aizawa Y, Takahashi M. WT1 peptide vaccination in a CML patient: induction of effective cytotoxic T lymphocytes and significance of peptide administration interval. Med Oncol 2011, 28(1):219-230. 10.1007/s12032-010-9425-3, 20107936.
45. Tsuboi A, Oka Y, Ogawa H, Elisseeva OA, Li H, Kawasaki K, Aozasa K, Kishimoto T, Udaka K, Sugiyama H. Cytotoxic T-lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination. J Clin Immunol 2000, 20(3):195-202. 10.1023/A:1006637529995, 10941827.
46. Chaise C, Buchan SL, Rice J, Marquet J, Rouard H, Kuentz M, Vittes GE, Molinier-Frenkel V, Farcet JP, Stauss HJ, Delfau-Larue MH, Stevenson FK. DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance. Blood 2008, 112(7):2956-2964. 10.1182/blood-2008-02-137695, 18502835.
47. Greiner J, Ringhoffer M, Taniguchi M, Li L, Schmitt A, Shiku H, Döhner H, Schmitt M. mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. Int J Cancer 2004, 108(5):704-711. 10.1002/ijc.11623, 14696097.
48. Quintarelli C, Dotti G, Hasan ST, De Angelis B, Hoyos V, Errichiello S, Mims M, Luciano L, Shafer J, Leen AM, Heslop HE, Rooney CM, Pane F, Brenner MK, Savoldo B. High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. Blood 2011, 117(12):3353-3362. 10.1182/blood-2010-08-300376, 3069675, 21278353.
49. Molldrem J, Dermime S, Parker K, Jiang YZ, Mavroudis D, Hensel N, Fukushima P, Barrett AJ. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 1996, 88(7):2450-2457.
50. Qazilbash MH, Wieder E, Rios R, Lu S, Kant S, Giralt S, Estey EH, Thall P, de Lima M, Couriel D, Champlin RE, Komanduri K, Molldrem JJ. Vaccination with the PR1 leukemia-associated antigen can induce complete remission in patients with myeloid leukemia [abstract]. Blood 2004, 104:259. (ASH Annual Meeting Abstracts).
51. Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J, Jafarpour B, Boss C, Barrett AJ. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008, 111(1):236-242. 10.1182/blood-2007-08-108241, 2200809, 17875804.
52. Greiner J, Schmitt A, Giannopoulos K, Rojewski MT, Götz M, Funk I, Ringhoffer M, Bunjes D, Hofmann S, Ritter G, Döhner H, Schmitt M. High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Haematologica 2010, 95(7):1191-1197. 10.3324/haematol.2009.014704, 2895045, 20081055.
53. Tzankov A, Strasser U, Dirnhofer S, Menter T, Arber C, Jotterand M, Rovo A, Tichelli A, Stauder R, Günthert U. In situ RHAMM protein expression in acute myeloid leukemia blasts suggests poor overall survival. Ann Hematol 2011, 90(8):901-909. 10.1007/s00277-011-1159-6, 21274712.
54. Li Z, Qiao Y, Liu B, Laska EJ, Chakravarthi P, Kulko JM, Bona RD, Fang M, Hegde U, Moyo V, Tannenbaum SH, Ménoret A, Gaffney J, Glynn L, Runowicz CD, Srivastava PK. Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia. Clin Cancer Res 2005, 11(12):4460-4468. 10.1158/1078-0432.CCR-05-0250, 15958631.
55. Wei G, Ni W, Chiao JW, Cai Z, Huang H, Liu D. A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. J Hematol Oncol 2011, 4:46. 10.1186/1756-8722-4-46, 3230125, 22082134.
56. Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW, Hofmann WK, Uharek L, Thiel E, Scheibenbogen C. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009, 113(26):6541-6548. 10.1182/blood-2009-02-202598, 19389880.
57. Cen D, Hu G, Zhou Y, Yang L, Chen S, Schmidt CA, Li Y. Enhancement of specific cellular immune response induced by DNA vaccines encoding PML-RARalpha and hIL-2 genes. Hematology 2010, 15(2):88-95. 10.1179/102453310X125833470096589073, 20423569.
58. Ji MC, Jiang YW, Liu W, Guan J, Qian L, Gong WJ. Immune protective mechanisms of gene vaccines with co-expressing bcr-abl fusion gene fragment and mouse IL-7 gene. Zhonghua Zhong Liu Za Zhi 2007, 29(2):93-95. Chinese.
59. Tao K, Li YJ, Wang D, Qi JY, Deng YP, Wang HX, Hu J, Feng WL. Enhancement of specific cellular immune response induced by glycosyl-phosphatidylinositol-anchored BCR/ABL and mIL-12. Cancer Biol Ther 2011, 12(10):881-887. 10.4161/cbt.12.10.17674, 3280903, 22024730.
60. Šmahel M, Poláková I, Sobotková E, Vajdová E. Systemic administration of CpG oligodeoxynucleotide and levamisole as adjuvants for gene-gun-delivered antitumor DNA vaccines. Clin Dev Immunol 2011, 2011:176759. 3199051, 22028727.
61. Eslami NS, Shokrgozar MA, Mousavi A, Azadmanesh K, Nomani A, Apostolopoulos V, Day S, Amanzadeh A, Alimohammadian MH. Simultaneous immunisation with a Wilms' tumour 1 epitope and its ubiquitin fusions results in enhanced cell mediated immunity and tumour rejection in C57BL/6 mice. Mol Immunol 2012, 51(3-4):325-331.
62. Shen C, Hao SG, Zhao CX, Zhu J, Wang C. Antileukaemia immunity: effect of exosomes against NB4 acute promyelocytic leukaemia cells. J Int Med Res 2011, 39(3):740-747.
63. Liu MA. DNA vaccines: an historical perspective and view to the future. Immunol Rev 2011, 239(1):62-84. 10.1111/j.1600-065X.2010.00980.x, 21198665.
64. Quaglino E, Iezzi M, Mastini C, Amici A, Pericle F, Di Carlo E, Pupa SM, De Giovanni C, Spadaro M, Curcio C, Lollini PL, Musiani P, Forni G, Cavallo F. Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. Cancer Res 2004, 64(8):2858-2864. 10.1158/0008-5472.CAN-03-2962, 15087404.
65. Curcio C, Khan AS, Amici A, Spadaro M, Quaglino E, Cavallo F, Forni G, Draghia-Akli R. DNA immunization using constant-current electroporation affords long-term protection from autochthonous mammary carcinomas in cancer-prone transgenic mice. Cancer Gene Ther 2008, 15(2):108-114. 10.1038/sj.cgt.7701106, 17992201.
66. Cheung YK, Cheng SC, Sin FW, Xie Y. Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection. Vaccine 2004, 23(5):629-638. 10.1016/j.vaccine.2004.07.010, 15542183.